Trial · NCT07891741
Study of 3D Ultrasound for Support of Hemodialysis Cannulation
NCT07891741, Not applicable, Recruiting, Sonavex, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of 3D Ultrasound for Support of Hemodialysis Cannulation. Trials, record NCT07891741. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891741
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of 3D Ultrasound for Support of Hemodialysis Cannulation
- NCT number
- NCT07891741
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Sonavex, Inc.
- Conditions
- Dialysis
- Interventions
- EchoMap, Standard of Care Cannulation
- First posted
- 2026-10-23
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Stage 1: Successful Cannulation Sessions | Up to 24 weeks | Number of dialysis sessions with successfully cannulated for dialysis treatment of the fistula |
| Primary | Stage 1: Number of Sticks | Up to 24 weeks | The number of times a needle penetrated the skin during a cannulation attempt |
| Primary | Stage 1: Number of Needle Advancements | Up to 24 weeks | How many times a needle was advanced, regardless of how many needles were used |
| Primary | Stage 1: Number of Cannulation Related Infiltrations | Up to 24 weeks | Perforation of the side or deep wall of the fistula resulting in pain, swelling, hematoma formation, or temporary or permanent loss of blood flow through the needle. |
| Primary | Stage 1: Presence and Severity of Infiltration Related Hematoma | Up to 24 weeks | Grade 1 - Stable hematoma and patient is able to initiate hemodialysis via the fistula as intended. Grade 2 - Stable hematoma, but patient is unable to initiate dialysis via the fistula as intended, or requires the use of a catheter or an intervention to use the fistula for hemodialysis, for one or more dialysis treatments. Grade 3 - Major complication where the vessel has ruptured. Hematoma is unstable and requires treatment to save fistula or fistula is lost. |
| Primary | Stage 1: Missed Dialysis Session | Up to 24 weeks | Number of missed dialysis due to a cannulation failure or injury |
| Primary | Stage 1: CVC Used | Up to 24 weeks | Whether a catheter was used for one or two needles due to an inability to cannulate or cannulation failure |
| Primary | Stage 1: CVC Placement | Up to 24 weeks | Whether a catheter was placed for dialysis due to cannulation failure or injury |
| Primary | Stage 1: Blood Stream Infections | Up to 24 weeks | Number of bloodstream infections |
| Primary | Stage 1: Freedom from device related adverse events | Up to 24 weeks | Number of device related adverse events |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R44DK131644 | Clinical Trial to Demonstrate Impact of an AI-enabled 3D Ultrasound-based Guidance System in Reducing Arteriovenous Fistula Cannulation Injury and Improving Patient Quality of Life | KANG, XIN | SONAVEX, INC. | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2021 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891741
GET https://conductscience.org/api/trials/v1/NCT07891741/registered